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Abstract
Background Cancer cachexia (cancer-induced muscle wasting) is found in a subgroup of cancer patients leaving the patients
with a poor prognosis for survival due to a lower tolerance of the chemotherapeutic drug. The cause of the muscle wasting in
these patients is not fully understood, and no predictive biomarker exists to identify these patients early on. Skeletal muscle
loss is an inevitable consequence of advancing age. As cancer frequently occurs in old age, identifying and differentiating the
molecular mechanisms mediating muscle wasting in cancer cachexia vs. age-related sarcopenia are a challenge. However, the
ability to distinguish between them is critical for early intervention, and simple measures of body weight may not be
sufﬁciently sensitive to detect cachexia early.
Methods We used a range of omics approaches: (i) undepleted proteome was quantiﬁed using advanced high mass accuracy
mass spectrometers in SWATH-MS acquisition mode; (ii) phospho epitopes were quantiﬁed using protein arrays; and (iii)
morphology was assessed using ﬂuorescent microscopy.
Results We quantiﬁed the soluble proteome of muscle biopsies from cancer cachexia patients and compared them with
cohorts of cancer patients and healthy individuals with and without age-related muscle loss (aka age-related sarcopenia).
Comparing the proteomes of these cohorts, we quantiﬁed changes in muscle contractile myosins and energy metabolism
allowing for a clear identiﬁcation of cachexia patients. In an in vitro time lapse experiment, we mimicked cancer cachexia
and identiﬁed signal transduction pathways governing cell fusion to play a pivotal role in preventing muscle regeneration.
Conclusions The work presented here lays the foundation for further understanding of muscle wasting diseases and holds the
promise of overcoming ambiguous weight loss as a measure for deﬁning cachexia to be replaced by a precise protein signature.
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Introduction
Skeletal muscle develops from mono-nucleated myoblasts
into multi-nucleated myotubes which then mature into
myoﬁbres, a process termed myogenesis.1 Once develop-
ment is complete, skeletal muscles are essential for locomo-
tion and respiration.2 Beyond the obvious role in
locomotion, skeletal muscle is a metabolically important
organ for glucose uptake and storage and a reservoir for
amino acids.3 As such, it is not surprising that metabolic
diseases such as type II diabetes can alter the composition
of muscle tissue.4 Skeletal muscle is plastic and responds to
use (and disuse), ageing, and disease. In elderly people,
several of these conditions may co-exist, and the cause of
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muscle wasting could not easily be allocated to a single
condition. Hence, a molecular description of these different
groups may hold the key to unequivocally differentiate
between normal age-related muscle loss and chronic
disease-related muscle wasting.5–7 Weight loss and muscle
wasting as a result of chronic disease such as cancer, heart
failure, renal failure, or chronic obstructive pulmonary
disease is termed cachexia.8 Currently, it is challenging to
differentiate between muscle loss due to age-related
sarcopenia or cachexia, but distinguishing them is critical for
early intervention.9 The most common method used in clinics
to differentiate modes of muscle loss is body weight
measurement over six months in combination with muscle
strength assessment.10,11 Despite weight stability, skeletal
muscle loss can still occur in elderly people.12 Hence, a more
specialized current clinical assessment of muscle utilizes dual
energy X-ray absorptiometry (DXA) scans to obtain accurate
measurement of muscle mass. A DXA scan in combination
with height measurements is used to calculate a relative
skeletal muscle index (RSMI).
Identiﬁcation of the underlying molecular mechanisms
involved in cancer cachexia (cca) remains elusive. It may
possibly be that different mechanisms causing cca may
require different therapeutic approaches. In light of techno-
logical advancements, omics and systems biology approaches
have started to shine light onto the molecular pathology of
muscle-related diseases.13 The main analytical challenge for
proteomics as an unbiased tool for protein quantiﬁcation is
the composition of muscle tissue itself. Global protein
identiﬁcation and quantiﬁcation are limited due to the high
number of contractile muscle proteins that make the analysis
of low abundant proteins challenging. Further, structural
proteins are frequently homologous in terms of protein
sequence, allowing only quantitative statements about
protein groups. In addition, a high number of contractile
muscle proteins lead to an ion suppression effect thus
masking underlying signaling proteins.14
In the past, proteomic studies of skeletal muscle included
1D or 2D peptide separation in combination with cation
exchange chromatography and liquid chromatography
coupled to tandem mass spectrometer (LC–MS/MS) to
generate a catalogue of proteins identiﬁable in human
muscle biopsies.15,16 Advances in analytical technologies
allowed for the expansion of the detectable proteome in
both animal biopsies and cell line models.17 By isolating
single mouse muscle ﬁbres, Murgia and co-workers were able
to quantify proteomes speciﬁc to fast or slow muscles
revealing an unexpected muscle type speciﬁc mitochondrial
adaptation.18 Other proteomic studies investigated the
plasticity of the muscle tissue proteome from human biopsies
over a variety of clinically observed situations. Brocca and
colleagues quantiﬁed proteome changes due to disuse using
2D electrophoresis and found myoﬁbrillar proteins, metabolic
enzymes, and antioxidant defense systems down-regulated
after 35 days of bed rest.19 Staunton and coworkers charac-
terized proteome changes due to age-dependent muscle loss
and detected changes in muscle metabolism, ion handling,
and the cellular stress response as a function of aging.20
Besides physical and age-dependent proteome changes,
genetic diseases also perturb the normal proteome in
muscles.21 Doran and colleagues investigated the effects of
the inheritable neuromuscular disorder Duchenne muscular
dystrophy using 2D gel electrophoresis and identiﬁed 35 at
least two-fold differentially regulated proteins comparing a
normal with a dystrophin-deﬁcient diaphragm.22 Overall,
these studies show a remarkable increase in proteins
identiﬁable from skeletal muscle tissue as LC–MS/MS
instrumentation advances. Besides identifying proteins and
validating them as function of genetic background or
environmental factors, identifying signal transduction
responsible for the observed changes is rare. Further, none
of these studies quantiﬁed the proteome of cachectic
patients or mimicked cachexia in vitro in order to understand
the molecular pathology underlying cachexia disease, which
leaves patients with a very poor prognosis.
Hence, we quantiﬁed the proteome of muscle biopsies
from diagnosed cca patients and three control groups:
weight-stable cancer (wsc), healthy non-sarcopenic (hns),
and age-related sarcopenia (ars) using an advanced unbiased
proteomics method termed SWATH-MS which takes
advantage of the latest generation high mass accuracy mass
spectrometers coupled to liquid chromatography
(Schema 1A).23 We found the muscle proteome composition
in cca to be quantitatively different from control groups,
identiﬁed protein modules representing this robust protein
signature, and validated main components in a separate
cohort of cca patients (Schema 1B). To further elucidate the
molecular mechanisms of cachexia, we used myoblasts from
an 83-year-old donor and quantiﬁed myogenesis as a
function of time and perturbation using a single cytokine
(tumor necrosis factor α, TNFα) (Schema 1C) to mimic the
disease condition. Signal transduction changes as a function
of perturbation were quantiﬁed using multiplexed
antibody-based protein microarrays. Altered protein
modules identiﬁed in vitro system were correlated back to
patient derived proteomics data and conﬁrmed by Western
blotting.
Methods
Patients/volunteers
All participants gave written informed consent prior to study
entry. All procedures were approved by the NHS Lothian
Research Ethics Committee. The study conformed to the
standards set by the Declaration of Helsinki.
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Nineteen cancer patients were identiﬁed via the upper
gastrointestinal cancer multi-disciplinary team at the Royal
Inﬁrmary, Edinburgh, UK. Patients had newly diagnosed po-
tentially resectable cancer. Pre-morbid weight was recalled
by the cancer patients and veriﬁed where possible from
the medical notes. Individual weight-loss was calculated
and expressed as a percentage of pre-morbid body weight
loss. Patients were considered cancer cachectic if they had
lost more than 5% of their pre-morbid weight (23). The
second group of cancer patients was considered as the
wsc patients.
All healthy elderly participants aged >75 years were
recruited using advertisements in local newspapers. Based
on their responses to previously published health selection
criteria,7,24 all individuals were healthy and did not engage
in any form of physical training. Based on DXA, these individ-
uals were classiﬁed as non-sarcopenic healthy elderly or age-
related sarcopenic. Criteria for this classiﬁcation was based
on the RSMI ((mass of skeletal muscle in kg) / ((body height
in m)2)) below 7.26 (men) and 5.45 (women).25 C-reactive
protein was measured in serum using an automated
hospital-based technique (Abbott TDX).
A Bergstrom needle muscle biopsy was obtained from the
lateral mass of the quadriceps under local anaesthetic.
The biopsy was cleaned of gross blood contamination and
snap frozen in liquid nitrogen and stored at 80 °C.
Dual-energy X-ray absorptiometry (Hologic Discovery A)
was used to measure body composition (i.e. fat mass, lean
mass, and bone mineral content). See Table 1 for patient
demographics.
Cell culture and treatment
Human skeletal muscle cells from an 83-year-old donor
(HuSkMCs; Cook Myosite Inc, PA 15238, USA) were cultured
for six days at 37 °C, 5% CO2 in growth medium consisting
of Myotonic basal medium (Cook Myosite Inc, PA 15238,
USA) supplemented with Myotonic growth supplement
(Cook Myosite Inc, PA 15238, USA), 20% FCS (Thermo Fischer
Scientiﬁc), 100 μg/mL ampicillin (Sigma Aldrich), and
10 μg/mL Insulin (Amimed). Cells were then seeded in
collagen-coated 96-well plates (25 000 cells/well) and in six-
well plates (500 000 cells/well). After 24 h, cells were washed
once with differentiation medium consisting of Myotonic
differentiation medium (Cook Myosite Inc, PA 15238, USA)
supplemented with 1% FCS (Thermo Fischer Scientiﬁc) and
100 μg/mL ampicillin (Sigma Aldrich). Cells were starved for
3 h at 37 °C in differentiation medium. Subsequently,
HuSkMCs were treated with 1 ng/mL TNFα (R&D system)
for different time frames (30 min, 1 h, 3 h, 24 h, 48 h, and
72 h). At the end of incubation, all the plates were washed
with phosphate-buffered saline (PBS) and further processed
for the different assays described below.
Schema 1 Project overview. (A) There are four cohorts: cancer cachexia, weight-stable cancer, age-related sarcopenic, and non-sarcopenic. Latter two
cohorts are deﬁned as healthy elderly. Muscle needle biopsies were taken from patients and the proteome extracted using tissue grinding. Extracted
proteins were digested and puriﬁed peptides analysed using liquid chromatography coupled to tandem mass spectrometer (LC–MS/MS). (B) Proteins
were quantiﬁed across patients and statistical signiﬁcance analysis performed. Third-order data integration was used to determine proteins of interest,
especially differentiating between sarcopenic and cachexic patient groups. (C) Time-resolved myogenesis of myoblasts from an 83-year-old donor were
grown for 72 h without perturbation and with single cytokine (tumor necrosis factor α (TNFα)). Immunohistochemistry data was supplemented with
quantitative proteomics as a function of time using antibody-based protein arrays and LC–MS/MS.
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Immunoﬂuorescence
Human skeletal muscle cells growing in 96-well plates were
ﬁxed with 4% paraformaldehyde and washed once with PBS.
For permeabilization, cells were rinsed once in 0.5%
Triton/cytoskeleton stabilizing buffer (80 mM PIPES, 5 mM
EGTA, 1 mM MgCl2, 40 g/L PEG3500 in distilled water) for
15 min. After washing with PBS, cells were incubated in 10%
normal goat serum (Invitrogen) to avoid unspeciﬁc binding. Pri-
mary antibodieswerediluted inPBSand incubatedovernight at
4 °C. Cellswere thenwashed twicewith cytoskeleton stabilizing
buffer and incubated with secondary antibody diluted in PBS
for 1 h at room temperature. Images were acquired with CellR
software (Olympus) on a ﬂuorescence microscope (Olympus
IX81-ZDC) and further processed with the Fiji program.
Protein extraction
Proteins were extracted from pulverized human skeletal mus-
cle tissue by homogenizing the samples in the Precellys 24
system. Brieﬂy, 300 μL of PhosphoSafe Extraction Reagent
(Millipore) was added to minced and ground human skeletal
muscle tissue (8 mg) in Precellys 24 lysing kit tubes. Tissue
was further homogenized using the high-throughput homog-
enizer Precellys 24, for 10 s.). After incubation on ice for
5 min, the lysates were spun at 800 g for 5 min at 4 °C.
Supernatants were transferred into new tubes and spun for
another 12 min at 1600 g at 4 °C. Pellets (insoluble fraction)
were stored at 80 °C until further us. Supernatants were
collected and protein concentrations measured using the
BCA Protein Assay Kit (Pierce) with BSA as a standard.
Afterwards, phosphatase inhibitor cocktail (Roche) was
added, and the samples were stored at 80 °C until further
use. For protein extraction of human muscle cells, the same
method was used. Human skeletal muscle cells cultured in
six-well plates were lysed with 200 μL of PhosphoSafe
Extraction Reagent (Millipore) following the same procedure
using the Precellys 24 system for homogenization.
Western blot
Ten micrograms of protein extracts in reducing Laemmli SDS
sample buffer was boiled for 5min at 95 °C and then separated
by sodium dodecyl sulfate polyacrylamide gel electrophoresis
on 4–20% gradient gels (Bio-Rad, Cressier, Switzerland),
blotted to nitrocellulose membranes (Bio-Rad) using the
Trans-Blot Turbo Transfer System (Bio-Rad), blocked for 1 h in
blocking buffer (5% non-fat milk in Tris-buffered saline 0.05%
Tween-20), incubated overnight with primary antibody, rinsed,
and incubated for 1 h with peroxidase-conjugated goat anti-
rabbit IgG at room temperature. Blots were developed using
enhanced chemiluminescence (Roche, Rotkreuz, Switzerland)
or SuperSignal West Femto substrate (Thermo Scientiﬁc,
Wohlen, Switzerland) and exposed to Kodak ﬁlm (Kodak, Roch-
ester, NY, USA). Antibodies usedwere ERK1/2mousemonoclo-
nal clone L34F12, P-ERK1/2 (Thr202/Tyr204) (197G2), and
Tubulin (11H10) were from Cell Signaling Technologies (Dan-
vers, MA, USA). ATP5A (7H10BD4F9) to ATP5H (7F9BG1) were
from Abcam (Cambridge, UK); ROCK1 Antibody (EP786Y) from
Novus Biologics (Littelton, CO, USA), Anti-β-Actin, Clone AC-74
from SIGMA (St Louis, MO, USA); Rabbit polyclonal: Phospho-
FAK (Tyr576/577), Phospho-FAK (Tyr397), and FAK were from
Cell Signaling Technologies (Danvers, MA, USA); Troponin I fast
skeletal and mtHSP70 were from Abcam (Cambridge, UK); rab-
bit monoclonal Phospho-NF-kB p65 (93H1) (Ser536), Coﬁlin
(D3F9), Phospho-Akt (Thr308) (244F9), Phospho-Coﬁlin (Ser3)
Table 1 Patient demographics
Cancer patients (n = 19) Healthy volunteers (n = 18)
Non-cachexia (n = 14) Cachexiaa (n = 5) Non-sarcopenic (n = 10) Sarcopenicb (n = 8)
M:F 12:2 3:2 6:4 4:4
Age 66.3 (10.2) 64 (4.1) 77.4 (2.3) 80.3 (3.9)
Weight (kg) 81 (14.7) 89.6 (19.1) 73.4 (13.8) 61.1 (7.7)
Height (cm) 174.6 (9.5) 170.2 (2.7) 165.1 (7.6) 163.5 (6.1)
BMI 25.9 (3.8) 25.8 (4.7) 26.6 (4.1) 22.8 (2.6)
% WL 2.3 (3.2) 15.9 (6.8) — —
LBM (kg) 47.2 (6.8) 43.7 (6) 50.3 (10) 43.3 (7)
FM (kg) 18.8 (6.4) 17 (3.5) 20.9 (6.4) 15.8 (4.2)
ASM (kg/m2) 6 (0.6) 5.9 (0.8) 7.7 (1.3) 6.3 (0.9)
Cancer type
Gastric
Oesophageal
OGJ
Pancreas
1
4
2
7
0
1
0
4
—
—
—
—
—
—
—
—
CRP (mg/L) 19.8 (44.7) 15.8 (17.3) 3.2 (2.5) 3.4 (2.8)
% > 10 mg/L 29 40 0 0
Values are mean and s.d.
aDeﬁned by >10% WL.
bBaumgartner’s criteria.
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(77G2), and Akt (pan) (11E7) were from Cell Signaling
Technologies (Danvers, MA, USA)
Western blots were analysed densitometrically using
ImageJ software version 1.45 (NIH, Bethesda, MD, USA;
http://rsbweb.nih.gov/ij). Band intensity of each sample was
normalized to coomassie blue stained gels.
Immunohistochemistry
The following antibodies were used: immunoﬂuorescence
primary antibodies: mouse α-Myosin (skeletal, fast) (1:500,
Sigma), rabbit α-Desmin (1:200, Sigma), secondary antibod-
ies: goat α-rabbit IgG (H + L) alexa ﬂuor 488 F (ab0) 2 fragment
(1:750, Invitrogen), and goat α-mouse IgG (H + L) alexa ﬂuor
488 F (ab0) 2 fragment (1:750, Invitrogen).
Protein array
The Kinexus Antibody Microarray KAM-850 analyses were
performed on protein lysates of HuSkMCs. Cells were lysed
in 200 μL per well using KAM-850 kit lysis buffer. Protein
lysates were transferred in mpbio lysing matrix D tubes, and
preparation was conducted using a fast prep machine (MP
Biomedicals) as described in the protocol and on the Kinexus
InternetWeb site at www.kinexus.ca. Brieﬂy, 50 μg of HuSkMc
lysate proteins was labeled with the kit ﬂuorescent dye at a
concentration of 2 mg/mL, and unincorporated dye molecules
were removed by centrifugation on desalting columns
(provided in the kit), and total ﬂuorescence was measured
on a Spectramax Paradigm® reader using the Tune Cassette
(Molecular Devices, Sunnyvale, CA). Puriﬁed labeled proteins
from two samples were incubated separately on opposite
sides of a KAM-850 antibody microarray. This microarray fea-
tures two identical ﬁelds of antibody grids, each ﬁeld contain-
ing 517 pan-speciﬁc antibodies and 337 phospho-site-speciﬁc
antibodies. These antibodies are printed in duplicate. After
probing, arrays were scanned using a GenePix® scanner
(Molecular Devices, Sunnyvale, CA) with a resolution of
10 μm, and resulting images were quantiﬁed using GenePix®
Pro 7 software (Molecular Devices, Sunnyvale, CA). Values
provided in theﬁgures are themeans of the recordedmeasure-
ments from each antibody spot pair normalized with the total
Protein Fluorescence obtained and measured after labeling.
Cell lysis and peptide generation for liquid
chromatography coupled to tandem mass
spectrometer analysis
A detailed protocol for lysis and peptide clean-up for
LC–MS/MS can be found in the Supporting Information
peptide cleanup.
Liquid chromatography coupled to tandem mass
spectrometer analysis
The LC–MS/MS system used was an Eksigent NanoLC Ultra 2D
Plus HPLC system coupled to a 5600 TripleTOF mass
spectrometer (Sciex, Framingham, MA). Samples were
chromatographed using a 1D 2-h gradient from 2 to 35%
(buffer A 0.1% (v/v) formic acid, 2% (v/v) acetonitrile, buffer
B 0.1% (v/v) formic acid, 90% (v/v) acetonitrile) after direct
injection onto a 20-cm PicoFrit emitter (New Objective)
packed to 20 cm with Magic C18 AQ 3-μm 200-Å stationary
phase. For MS/MS acquisition in shotgun mode, top 20
most intense MS1 precursors (collected between 360 and
1460 m/z for 250 ms) with charge states between 2 and 5
selected for MS2 fragmentation, with a 15-s exclusion
window. Fragment MS2 ions were collected for 100 ms across
a 50–2000 m/z range. For MS/MS acquisition in SWATH-MS
mode,23 fragment windows were chosen as listed in the
Supporting Information (SWATH data analysis) and identical
LC gradient listed above. For anchoring SWATH maps during
the subsequent targeted analysis, reference iRT peptides
(Biognosys, Schlieren, Switzerland) were spiked into the
sample with a dilution of 1:20 v/v.
Shotgun data analysis
For targeted extraction of ion chromatograms from
SWATH-MS maps, four cell line samples (untreated and TNFα
at 0.5 h and 72 h) were analysed in shotgun mode. The
spectra were searched using the search engines X!TANDEM
Jackhammer TPP (2013.06.15.1—LabKey, Insilicos, ISB) and
Comet version ‘2013.02 rev. 2’ against the uniprot canonical
human protein (reviewed) database using Trypsin digestion
and allowing one missed cleavage. Included were
‘Carbamidomethyl (C)’ as static and ‘Oxidation (M)’ as vari-
able modiﬁcations. The mass tolerances were set to 15 ppm
for precursor ions and 0.1 Da for fragment ions. The identi-
ﬁed peptides were processed and analysed through the
Trans-Proteomic Pipeline (TPP v4.7 POLAR VORTEX rev 0,
Build 201403121010) using PeptideProphet, iProphet, and
ProteinProphet scoring. Spectral counts and peptides for
ProteinProphet were ﬁltered at false discovery rate (FDR) of
0.01 iprophet-pepFDR (=0.759 iprob). This analysis resulted
in 1751 proteins at 1% FDR (E1501221230) identiﬁed with
at least one peptide per protein.
SWATH data analysis
Sequential acquisition of all theoretical masses (SWATH-MS)
allows for consistent quantiﬁcation of proteins between
patient groups. SWATH-MS uses a time of ﬂight mass
analyser in combination with a fast high mass accuracy mass
Cancer cachexia proteome characterization 5
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spectrometer enabling consistent quantiﬁcation of peptides
across many samples. Hence, if a peptide is not detected in
SWATH-MS mode, it fell below the limit of detection, and
the stochastic sampling approach of traditional shotgun ex-
periments does not apply. For targeted extraction, a custom
SWATH-library was built using standard parameters,26 and
all SWATH assays deposited into a publically available SWATH
library.27 SWATH-MS maps were analysed using OpenSWATH
workﬂow28 (Supporting Information SWATH analysis). Protein
abundance values were calculated with two peptides per
protein minimum using aLFQ29 for in vitro myogenesis
experiments, while mapDIA v2.2.030 was used for statistical
analysis of patient data.
Results
Proteome isolation of muscle biopsies
To characterize cca in muscle tissue on a proteomics level, we
collected human biopsies (N = 36, Table 1). The samples in-
cluded healthy non-sarcopenic healthy elderly (hns, N = 10),
weight-stable cancer (wsc, N = 14), age-related sarcopenia
(ars, N = 8), and cachectic cancer patients (cca, N = 4). The
extracted soluble proteome was analysed using high mass
accuracy mass spectrometers operated in SWATH-MS mode,
which is a non-stochastic protein quantiﬁcation method
allowing for consistent quantiﬁcation of analytes between
patient-derived samples.23 The resulting digital record was
analysed in silico (see for details, Figure 1A). Initial protein
analysis per patient revealed that some patient proteome
proﬁles either contained a very low amount of protein IDs
or predominantly contained albumin and haemoglobin dom-
inating protein abundance measurements, suggesting a high
blood component within the muscle biopsy. Those samples
were excluded resulting in 26 muscle biopsies that were used
for further analysis. Normalized values for 521 proteins
across 26 samples are shown in an unsupervised clustered
heat map using Pearson correlation distance function
(Figure 1B). Next, we calculated the median coefﬁcient of
variance (CV) per patient group to be 0.4 (Figure 1C), which
is good considering a technical CV of 0.2 and quantiﬁcation
of primary patient material.
Alteration of muscle composition in cachexia
We ﬁrst compared proteome signatures from both healthy
elderly groups with wsc patients using mapDIA (see Supple-
mentary Data 1-mapDIA). This comparison resulted in 25 pro-
teins with a statistically signiﬁcant score of FDR < 9·1019,
while only seven proteins were at least two-fold differentially
regulated between patient groups (Figure 1D, upper panel).
The only muscle protein group with a differential protein ex-
pression was muscle contractile myosins (myosin heavy chain
1, 2, 3, 6, 7, 8: 7-MYHs) in which expression in healthy elderly
was reduced compared with wsc patients (FC log2 = 1.5,
FDR = 6.7·1010). Next, we compared proteomes from cca
with wsc patients. Statistical signiﬁcance analysis resulted in
57 proteins with a FDR < 9·1019 of which 44 proteins were
at least two-fold differentially expressed between the patient
groups (Figure 1D, lower panel). Lower expressed in cachectic
vs. wsc patients were Tropomyosin TPM1, 2 (FC log2 = 1.7,
FDR < 9·1019) together with a higher expression of muscle
contraction myosins (myosin heavy chain 1, 4, 8: 3-MYHs)
(FC log2 = 2.3, FDR < 9·10
19), suggesting a dramatic change
in conventional muscle composition in cachectic muscles vs.
muscles of wsc patients. Similarly, the comparison of cachec-
tic vs. healthy elderly muscle biopsies (Figure 1E, left panel)
showed higher expression of muscle contraction myosins
(myosin heavy chain 1, 2, 4, 8) in cca samples (FC log2 = 1.6,
FDR < 9·1019). Third, we compared ars with cca and identi-
ﬁed 34 proteins with a statistically signiﬁcant score of
FDR < 9·1019, while 29 proteins were at least two-fold dif-
ferentially expressed between the groups (Figure 1E, right
panel). Among the highest differentially regulated proteins
were muscle contraction myosins (myosin heavy chain 1, 4,
8) with a FC log2 = 2.3 (FDR< 9·10
19) which were more highly
expressed in cachexia compared with age-related sarcopenic
muscle. From these three analyses based on statistical signiﬁ-
cance and fold change, or ratio between conditions (FC) we
conclude that cca has a distinguishable proteome compared
with two other groups: healthy elderly (both sarcopenic and
non-sarcopenic) and wsc patients. There was no comparable
proteome signature identiﬁed in any other comparison be-
tween groups (see Supplementary Data 1-mapDIA). Even
within the healthy elderly group separated based on the RSMI
into non-sarcopenic and sarcopenic individuals, little change
in the actual proteome was observed. Hence, our proteome
analysis of needle biopsies of various cohorts revealed that
cca may be associated with speciﬁc protein markers.
Differentiation of cachexia vs. all other patient
groups
Our proteome analysis based on LC–MS/MS demonstrated
that there are two main groups: cachexia vs. all other elderly
(healthy sarcopenic and non-sarcopenic), and wsc. Although
the limited sample size does not allow for any sophisticated
statistical analysis, we wondered if there were any functional
modules differentially regulated between the patient groups.
To address this question, we median centred protein values
for the cachexia and all other patient samples. If the ratio
of these two median protein values was less than 0.5 or more
than 2, we considered them regulated. There were 89
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Figure 1 Proteomics data. (A) Overview of computational analysis of liquid chromatography coupled to tandem mass spectrometer (LC–MS/MS) data
acquired in SWATH mode. First, the mass spectrometer acquires the m/z ratio in a data independent fashion. Areas under the curve of co-eluting tran-
sitions are the basis for peptide quantiﬁcation. Automatically annotated peptides are ﬁltered based on quality scores and give rise to protein quanti-
ﬁcation, which are further analysed by mathematical and statistical algorithms. (B) Heatmap of all proteins quantiﬁed per patient (ars: age-related
sarcopenia, cca: cancer cachexia, hns: healthy non-sarcopenic, wsc: weight-stable cancer). (C) Violin plots of coefﬁcient of variance (CV) per patient
groups. (D, E) Volcano plots of statistical signiﬁcance analysis focusing on cachexic vs. other patient groups.
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regulated proteins which were then analysed by STRINGv1031
for high conﬁdence (>0.9) interactions with experimental
evidence. The STRINGv10 analysis clustered into four func-
tional entities: heme cluster, Fo complex, electron transfer
chain, and contractile ﬁbre (see Supplementary Data-
89_prot_sig). We excluded the heme cluster from further
analysis as this is most likely a result of muscle biopsy proce-
dure variance and not disease related. Focusing on the
remaining functional modules (Figure 2A), we chose 16 repre-
sentative proteins and plotted Euclidean distance clustered
protein values in a heat map shown in Figure 2B. Using this
16 protein signature, cachectic patients are grouped in a clus-
ter, and as little as two components could explain 90% of the
variance (Figure 2C). Intriguingly, using this 16 protein signa-
ture, a healthy individual clustered with cca patients, which
we speculate could indicate an undetected underlying
chronic disease causing cachexia in this individual. We are
currently collecting additional muscle biopsies to identify
which of these 16 proteins are resulting in a statistically
signiﬁcant protein signature able to differentiate between
cachectic and wsc patients.
To further support and validate protein modules identiﬁed
in our proteomics study, we compared our proteomics
results based on LC–MS/MS to global gene expression pro-
ﬁles based on mRNA microarray data from gastrointenstinal
cancer patients (N = 14) with cca (N = 13).32 Overall, our
proteomics data show a larger dynamic range of regulated
proteins comparing cca to weight stable cachexia patients
(Figure 2D). Our work and data from Dahlman and co-
workers clearly show a dysregulation of proteins GO anno-
tated as mitochondrial electron transport chain and focal
adhesion (Figure 2D). As both studies identiﬁed identical
pathways dysregulated in cca using alternative protein quan-
tiﬁcation methodologies and independent patient cohorts,
we believe that further proteome quantiﬁcation of cca
muscle biopsies will undoubtedly result in a robust protein
signature consisting of two or three proteins.
Time-resolved in vitro follow-up
Based on muscle biopsy proteomes, our initial pilot study
identiﬁed only two patient groups. Hence, we asked which
molecular mechanisms could underlie the observed changes.
To address this question, we turned to an in vitro myogenesis
system using human primary myoblast of an 83-year-old do-
nor which was commercial available from COOK Myosite.
Myoblasts were seeded and grown under standard cell cul-
ture conditions. To mimic perturbation typical of cachexia,
we added TNFα. In a time lapse experiment, we characterized
(perturbed) myogenesis using immunohistochemistry,
antibody-based protein array for quantifying signal transduc-
tion changes and undepleted proteome quantiﬁcation using
LC–MS/MS in SWATH-MS acquisition mode (Schema 1C).
To characterize the morphological changes of our in vitro
system, we stained cells with antibodies against different
ﬁlament systems (myosin heavy chain 2 and desmin) and with
nuclear stain 4″,6-diamidino-2-phenylindole (DAPI). The
resulting immuno-histochemistry was visualized by ﬂuores-
cence microscopy. Representative pictures showing the
progress of myogenesis are shown in Figure 3. Figure 3A,
top row, shows myogenesis as a function of time under
normal conditions using a myosin-fast antibody, which is a
marker for terminal differentiation. A characteristic progres-
sion of single cell (myoblast) to myoﬁbres within 48 h is
observed, which is in contrast to TNFα-treated myoblasts
where no signiﬁcant myoﬁbre formation is seen (Figure 3A,
bottom row). TNFα-treated cells appear to be trapped at a
precursor state, which morphologically resembles untreated
cells at 24 h. Figure 3B depicts a zoom-in of myoﬁbre struc-
tures of untreated (Figure 3B, left panel) multi-nucleated
myoﬁbres. In contrast, TNFα-treated myoblasts form only
single myosin strands (Figure 3B, right panel). Figure 3C
shows comparable staining of untreated and treated cells
with Desmin (green) and nuclei with DAPI (blue). From our
results, we conclude that failed myoﬁbre formation under
TNFα treatment is not due to loss of viability. However, prote-
ome quantiﬁcation using SWATH-MS methodology of the
same time samples shows a clear shift in proteins identiﬁed
comparing early with late time points. This shift in the prote-
ome was also found in the cytokine-treated cells indicating
ongoing differentiation of the cells (Figure 3D).
Signal transduction characterization
To explore what might cause the observed phenotypic im-
pairment, we quantiﬁed 332 epitopes using antibody-based
protein microarray (Kinexus) of untreated and TNFα-treated
myoblasts from an 83-year-old donor at 0.5, 1, 3, 24, 48,
and 72 h. First, we plotted the ratio of TNFα/untreated
epitopes per time point as violin plots (Figure 4A); hence,
the closer the values are to 1, the more similar are the
two conditions to each other. Overall, there appear to be
two responses: an initial response at 0.5 h, which diminishes
at 1 h with most epitopes of equal intensity in both
TNFα-treated and untreated samples. Starting at 3 h, a con-
stant increase in ratios can be observed until the maximum
at 48 h; 48 h exhibits also the largest difference in morphol-
ogy between the two treatment conditions: in untreated
cells, myoﬁbres appear, while in TNFα-treated cells, only
sporadic myoﬁbre precursors are apparent (Figure 3A).
Finally, at 72 h, the differences in epitopes quantiﬁed by
protein microarrays slowly diminish (Figure 4A). From this
global analysis, we conclude that even relatively small and
transient changes in phosphorylation levels caused by
treatment with TNFα are sufﬁcient to cause incomplete
myogenesis in treated cells.
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Figure 2 Third-order data analysis. (A) Protein–protein interaction analysis of highly regulated proteins with statistical signiﬁcance resulted in three
modules distinguishing cachexia from all other patients or healthy elderly. (B) Heatmap of proteins representing protein clusters identiﬁed above
(ars: age-related sarcopenia, cca: cancer cachexia, hns: healthy non-sarcopenic, wsc: weight-stable cancer). (C) Principle component analysis of protein
signature demonstrating that three proteins would be able to explain the variance differentiating between cachexic and all other patient groups. (D)
Cross validation of identiﬁed protein modules by alternative protein abundance measurements on independent cohort.32
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Figure 3 Immunohistochemistry of myogenesis. (A) Myogenesis as a function of time (3 to 72 h) and perturbation using tumor necrosis factor α
(TNFα). In blue, cell nuclei are stained using 4″,6-diamidino-2-phenylindole (DAPI), while in green, myosin-fast antibodies were used to stain for
myoﬁbres. (B) Zoom-in of terminal time point at 72 h: clearly visible are the multi-nucleated myoﬁbres in the untreated cells. In contrast, TNFα-treated
myoblasts did not differentiate into myoﬁbres. (C) Use of Desmin antibodies and DAPI staining demonstrates that muscle cells are viable in both con-
ditions. (D) Proteome quantiﬁcation using SWATH-MS: a four-way Venn diagram shows the proteome shift as a function of time and perturbation. The
heatmap shows protein values of differentially regulated proteins as sorted by Pearson correlation.
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Next, we interrogated individual quantiﬁed epitopes. One
example of expected differential protein signaling is
phosphorylated Nuclear factor NF-kappa-B. Nuclear factor
NF-kappa-B (NFkB) should remain non-phosphorylated in
untreated cells, while upon cytokine treatment, the
transcription regulator NFkB will be activated through
phosphorylation. As seen in Figure 4B, our antibody-based
protein array data conﬁrmed by Western blotting support
exactly the predicted pattern of high levels of p-NFkB in
TNFα-treated cells during early time points, while only
background levels of p-NFkB were observed in untreated
cells. Interestingly, levels of phosphorylation in treated cells
Figure 4 Time-resolved orthogonal proteome analysis. (A) Violin plot depicting ratio of TNFα/untreated from 332 protein epitopes quantiﬁed by pro-
tein array as function of time. (B) Individual key proteins selected from protein array data and normalized epitope values plotted as function of time.
Untreated values are shown in dark blue, while TNFα-treated cells are shown in light blue.
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are restored to background levels only after 72 h. To con-
ﬁrm inﬂammatory pathway activation, we determined
phosphorylation levels of P38. We detected a ﬁve-fold in-
crease in p-P38 levels at 0.5 h comparing untreated to
TNFα-treated myoblasts. Throughout the time course, p-
P38 levels in TNFα-treated cells were generally higher than
in untreated cells (see Supplementary-p-P38.pdf) Alongside
the detection of p-NFkB upon TNFα treatment, additional
phosphorylation of proteins was detected exclusively under
this condition. ERK1/2 is one such example in which total
ERK1/2 increases as a function of time and TNFα treat-
ment, while in untreated samples total ERK1/2 steadily de-
creases. Phospho-ERK1/2 (p-ERK1/2) decreases as a
function of time in both TNFα-treated and untreated sam-
ples, while at 72 h p-ERK1/2 is ﬁve times higher in TNFα-
treated cells (Figure 4B). Similarly, ROCK1 has a low expres-
sion level in untreated cells, while at 3 and 72 h the pro-
tein is expressed at high levels in TNFα-treated samples
(Figure 4B). Another typical behaviour is a time-dependent
activation and deactivation as a function of time in
untreated cells, e.g. p-Thr (308)-AKT (Figure 4B). Although
total AKT remains similar throughout the time course in
both untreated and treated samples, there is a clear
constant decrease of p-Thr (308)-AKT signal in TNFα-treated
cells, while in untreated cells there is an activation of this
phosphorylation site starting after 1 h and ending at
72 h. The p-Thr (308)-AKT signal co-insides with the
morphological appearance of myoﬁbres in untreated cells
(see Figure 3A). It is intriguing to note that p-Thr (308)-
AKT level at the ﬁnal 72 h time point is equal between
the two conditions. Another example of zero end point
difference is the aforementioned p-NFkB (Figure 4B). These
examples illustrate the importance of quantifying phosphor-
ylation and protein abundance changes throughout
myogenesis as single end-point analysis would have missed
key regulatory differences, e.g. p-NFkB.
Cell fusion
Focal adhesion kinase (FAK) plays a pivotal role in modulating
fusion of cells. Protein levels of FAK remain constant
throughout myogenesis (Figure 5A) in untreated and
TNFα-treated cells. However, autocatalytic phosphorylation
at Tyr397 is down-regulated two-fold in TNFα compared with
untreated cells at the 3 and 72-h time points (Figure 5A). At
the same time points, phosphorylation of RET and SCR at
Thr 576/577 is down-regulated four- and six-fold, respec-
tively, in TNFα-treated cells. Furthermore, under TNFα
treatment, levels of Thr 567/577 are four times higher at
30 min. Taken together, proper myogenesis and formation
of multi-nucleated myotubes occur only in untreated cells,
where FAK phosphorylation levels of Thr 567/577 slowly
increase in early time points and stay constant throughout
the time course. We see a correlation of impaired
myogenesis when FAK Thr 567/577 phosphorylation levels
ﬂuctuate by as much as 10-fold throughout the time course
in TNFα-treated cells. A time-lapse animation (Supplementary
Data-hsadd04510_frames.gif) shows how different parts of
the FAK signaling pathway are differentially activated as a
function of time and perturbation.
In untreated myogenesis, coﬁlin, a protein implicated in
cytoskeleton dynamics, steadily increases protein and phos-
phorylation levels until it doubled in intensity comparing
30-min with 72-h time points (Figure 5B). This is in contrast
to TNFα-treated cells where total coﬁlin is twice as high at
3 h and phosphorylation levels nearly ﬁve times higher in
TNFα compared with untreated at the same time. Further,
total and phosphorylated levels of coﬁlin spike again at
72 h compared with untreated cells (see Figure 5B). This
bimodal behaviour of increased protein amounts is mirrored
in tubulin (Figure 5B) and pan-actin (Figure 5A), but not
F-actin which remains nearly unchanged throughout
myogenesis (Figure 5A). It appears as if the amount of pan-
actin is less important in myogenesis than the steady 10-fold
increase of troponin (fast) per time point (comparing 24 h to
48 h and 48 h to 72 h) as shown in Figure 5C. The drastic
troponin (fast) increase coincides with appearance of
myotubes (see Figure 3A).
Our data suggest that TNFα blocks myotube formation via
dysregulation of key molecules of the FAK signaling pathway
resulting in dysregulation of proteins involved in cytoskeleton
dynamic and blocking of cell fusion.
Mitochondrial energy metabolism
Besides structural proteins, we also noted a dysregulation
of proteins involved in the mitochondrial electron transport
chain upon TNFα treatment. Under normal conditions,
members of the mitochondrial ATP synthase complex (F1
F0 ATP synthase or Complex V) are more abundant at the
48 and 72-h time points when compared with earlier time
points (see Figure 5C). In case of ATP5L and ATPO, both
proteins are not detectable at early time points, while they
are detectable at 48 and 72 h. ATPB is twice as abundant
at 48 and 72 h when compared with earlier time points.
Upon TNFα treatment, ATP synthase complex protein mem-
bers are less well coordinated. ATPO is detected only at the
48 and 72-h time points, while ATP5L is already detectable
in early time points. ATPB, which doubles in abundance in
untreated cells, remains constant under TNFα treatment.
We conclude that myotube formation in untreated
myoblasts requires higher energy consumption, which is
reﬂected in the increased amount of mitochondrial ATP
synthase complex.
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Discussion
Time lapse (perturbed) myogenesis proteome
quantiﬁcation
In an in vitro experiment, myoblasts from an 83-year-old donor
differentiated into myoﬁbre. Our time lapse quantiﬁcation
throughout myogenesis was essential to uncover dynamics
otherwise missed by endpoint comparisons, e.g. single end-
point comparison between untreated and TNFα-treated cells
at 72 h would have missed the dynamics of pNFkB entirely
(Figure 4B). Other notable differences were the detection
and quantiﬁcation of matrix metalloprotease-14 (MMP-14)
exclusively at the early time points of unperturbed myoblasts
but not in TNFα-treated cultures. Matrix metalloprotease-14
is vital for the migration of myoblasts into collagen I matrix33
and was also detected in the secretome of myoblasts during
differentiation.34 Hence, our data suggest that TNFα interferes
at a very early stage of myogenesis with expression of proteins
involved in muscle regeneration.
Our orthogonal investigation of myogenesis using immuno-
histochemistry, protein arrays quantifying phosphorylated
epitopes and protein abundance measurements using
SWATH-MS clearly shows that an orchestrated sequence of
signaling events together with protein abundance changes
results in myogenesis. Through the time course, observed
phosphoproteme changeswere small and transient upon TNFα
treatment. Our data suggest that TNFαblocks cell fusion via the
FAK signaling cascade (Figure 5). As a consequence of FAK
Figure 5 Time-resolved orthogonal proteome analysis of individual proteins and phosphorylation sites thereof: (A) focal adhesion pathway, (B) thin
muscle ﬁlament, and (C) energy homeostasis with dark blue lines representing untreated and light blue TNFα-treated cells.
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signal transduction perturbation, cellular actin structures are
formed but do not result in fused cells as evidenced by
immunohistochemistry. One possible mechanism of blocked
actin ﬁlament formation could be due to phosphorylation of
coﬁlin.35 Our data support this possible mechanism as there
is twice as much unphosphorylated coﬁlin in untreated
myoblasts at 72 h than in TNFα-treated cells (Figure 5).
Identiﬁcation of cachexia-speciﬁc protein signature
supported by in vitro time course data
We set out to characterize proteome changes based on
LC–MS/MS in skeletal muscles of cca patients and compared
this group to three related cohorts: hns, ars, and wsc.
Through consistent protein quantiﬁcation by acquiring
LC–MS/MS data in SWATH mode and fold change analysis,
we identiﬁed the cachexia proteome to be distinct from all
other cohorts in our study. The fold change analysis was
followed by a protein network analysis which revealed three
distinct functional modules affected by cachexia: Fo complex,
electron transport chain, and contractile ﬁbre. Reduced levels
of electron transport chain proteins were also reported for
skeletal muscles of chronic obstructive pulmonary disease
patients.36 Dysregulation of mitochondrial electron transport
chain and focal adhesion was also observed by Dahlman and
co-workers in cca patients.32 Our results show that the
combination of mitochondrial dysfunction and contractile
ﬁbre alterations will hold the key to a cachexia-speciﬁc
protein signature.
This protein signature originating from patient muscle
biopsies is further supported by our in vitro myogenesis
experiments in which myoblasts differentiate into myoﬁbres
or arrested in pre-myoﬁbre state due to treatment with
TNFα. Quantifying the proteome as a function of time, we
found that the ATP synthase complex is up-regulated at the
later time points of myogenesis, suggesting that myotubes
have an elevated energy consumption in comparison with
single cell myoblasts as quantiﬁed by both LC–MS/MS and
antibody-based protein arrays. In patient samples quantiﬁed
by SWATH-MS, ATP synthase complex was identiﬁed in the
initial 89 protein signature based on fold change and statisti-
cal signiﬁcance analysis. The complex also propagated to the
ﬁnal protein signature as multiple complex members showed
large fold changes and proteins were connected by high con-
ﬁdence protein–protein interactions (STIRNGv10). ATP5A was
orthogonally quantiﬁed using Western blotting and is a prom-
ising candidate for a ﬁnal protein signature able to reliably
identify cachectic patients. We are collecting additional skel-
etal muscle samples from cachectic and weight-stable patient
groups and will quantify the identiﬁed protein signature
across a larger cohort of patients using targeted proteomics37
to identify a robust protein signature of cachexia with
statistical signiﬁcance.
Protein signature for altered skeletal muscle
regeneration
Our study focused on altered muscle regeneration as a conse-
quence of cancer, an underlying chronic disease. It should be
noted that not all cancers necessarily cause cachexia.38
Similarly, skeletalmuscle regeneration can be affectedbymore
than just cancer. In muscle atrophy, the balance between syn-
thesis of new proteins and degradation of existing proteins is
tipped towards the latter.39 Atrophy in myotubes was induced
by expressing ubiquitin ligase muscle atrophy F-box (MAFbx)
in a rodentmodel.40 Consistent with this observation, mice de-
ﬁcient in either ubiquitin ligaseMAFbxorMuscle RING Finger 1
(MuRF1) were resistant to atrophy.40 Besides degradation of
proteins via the ubiquitin proteasome degradation pathway,
the autophagy lysosomal degradation pathway is similarly
important in skeletal muscles.41 Both protein degradation
pathways are controlledbyForkheadboxproteinO3 (FoxO3).42
Our study focused on cachexia where altered regenera-
tion plays an important role in muscle wasting associated
with cancer. We quantiﬁed a clear proteomic difference in
muscle between cca and all other cohorts, some of which
are affected by disease (cancer), others are healthy elderly
(>75 years), and some of which show low RSMI. Our ﬁnd-
ings demonstrate that conventional weight loss measure-
ments could be replaced by protein quantiﬁcation with
potential for early disease detection as seen by the heat
map clustering (Figure 2B). Following these initial ﬁndings,
we supported the identiﬁed protein signature by in vitro
model system differentiating myoblasts of an 83-year-old
donor into myoﬁbres, a process interrupted by a single
cytokine TNFα. Tumor necrosis factor α impairs myogenesis
on multiple levels: from altering protein expression patterns
of vital muscle regenerative proteins, e.g. MMP-14, over in-
terference with FAK signaling pathway effecting actin-coﬁlin
tube formation to dysregulated ATP synthase complex when
compared with untreated myoﬁbres. Hence, we are
conﬁdent that a robust protein signature based on proteins
belonging to the Fo complex, electron transport chain, and
contractile ﬁbre will be identiﬁed in follow-up studies com-
prised of more patient samples.
Acknowledgements
This work was supported by a Transfer Project grant from
SystemsX.ch, The Swiss Initiative in Systems Biology.
Author contributions
H.A.E. and C.J. conceived the work. H.A.E., S.D., V.T., A.S., K.C.
H.F., N.J., and C.A.G. collected data. H.A.E., C.J., and K.C.H.F.
analysed and interpreted data. H.A.E. and C.J. drafted the
manuscript. H.A.E., N.J., C.A.G., K.C.H.F., R.A., and CJ critically
14 H. A. Ebhardt et al.
Journal of Cachexia, Sarcopenia and Muscle 2017
DOI: 10.1002/jcsm.12188
revised the manuscript. All authors read and approved the
submitted manuscript. Also, the authors certify that they
comply with the ethical guidelines for publishing in the
Journal of Cachexia, Sarcopenia, and Muscle: update 2015.43
Online supplementary material
Additional Supporting Information may be found in the online
version of this article at the publisher's web-site:
Supporting Information Supplementary Data 1-mapDIA
Supporting Information Supplementary Data-89_prot_sig
Supporting Information Supplementary
Data-hsadd04510_frames.gif
Supporting Information Supplementary-p-P38.pdf
Supporting Information peptide cleanup
Supporting Information SWATH data analysis
Supporting Information Supplementary-Abbreviations
Proteome data set: http://massive.ucsd.edu/ProteoSAFe/sta-
tus.jsp?task=ba010a5598294233a28638e886446477
Conﬂict of interest
The authors declare that they have no conﬂict of interest.
References
1. Zammit PS, Partridge TA, Yablonka-Reuveni
Z. The skeletal muscle satellite cell: the
stem cell that came in from the cold. The
journal of histochemistry and cytochemis-
try: ofﬁcial journal of the Histochemistry
Society 2006;54:1177–1191.
2. Bowen TS, Schuler G, Adams V. Skeletal
muscle wasting in cachexia and sarcopenia:
molecular pathophysiology and impact of
exercise training. J Cachexia Sarcopenia
Muscle. 2015;6:197–207.
3. Argiles JM, Campos N, Lopez-Pedrosa JM,
Rueda R, Rodriguez-Manas L. Skeletal
muscle regulates metabolism via interor-
gan crosstalk: roles in health and disease.
J Am Med Dir Assoc 2016;doi:10.1016/j.
jamda.2016.04.019.
4. Kelley DE, He J, Menshikova EV, Ritov VB.
Dysfunction of mitochondria in human
skeletal muscle in type 2 diabetes.
Diabetes 2002;51:2944–2950.
5. Cartee GD, Hepple RT, Bamman MM,
Zierath JR. Exercise promotes healthy
aging of skeletal muscle. Cell Metab
2016;23:1034–1047.
6. Macaluso A, De Vito G. Muscle strength,
power and adaptations to resistance train-
ing in older people. Eur J Appl Physiol
2004;91:450–472.
7. Mitchell WK, Williams J, Atherton P, Larvin
M, Lund J, Narici M. Sarcopenia,
dynapenia, and the impact of advancing
age on human skeletal muscle size and
strength; a quantitative review. Front Phys-
iol 2012;3:260, doi:10.3389/fphys.2012.
00260.
8. Evans WJ, Morley JE, Argiles J, Bales C,
Baracos V, Guttridge D, et al. Cachexia:
a new deﬁnition. Clin Nutr
2008;27:793–799.
9. Fearon KC. Cancer cachexia: developing
multimodal therapy for a multidimensional
problem. Eur J Cancer 2008;44:
1124–1132,.
10. Fearon KC, Voss AC, Hustead DS. Cancer
Cachexia Study G. Deﬁnition of cancer ca-
chexia: effect of weight loss, reduced food
intake, and systemic inﬂammation on
functional status and prognosis. Am J Clin
Nutr 2006;83:1345–1350.
11. Cruz-Jentoft AJ, Baeyens JP, Bauer JM,
Boirie Y, Cederholm T, Landi F, et al.
Sarcopenia: European consensus on deﬁni-
tion and diagnosis: Report of the European
Working Group on Sarcopenia in Older
People. Age Ageing 2010;39:412–423.
12. Gallagher D, Ruts E, Visser M, Heshka S,
Baumgartner RN,Wang J, et al. Weight sta-
bility masks sarcopenia in elderly men and
women. Am J Physiol Endocrinol Metab
2000;279:E366–E375.
13. Gallagher IJ, Jacobi C, Tardif N, Rooyackers
O, Fearon K. Omics/systems biology and
cancer cachexia. Semin Cell Dev Biol
2016;54:92–103.
14. Annesley TM. Ion suppression in mass spec-
trometry. Clin Chem 2003;49:1041–1044.
15. Parker KC, Walsh RJ, Salajegheh M, Amato
AA, Krastins B, Sarracino DA, et al.
Characterization of human skeletal muscle
biopsy samples using shotgun proteomics.
J Proteome Res 2009;8:3265–3277,
doi:10.1021/pr800873q.
16. Hojlund K, Yi Z, Hwang H, Bowen B, Lefort
N, Flynn CR, et al. Characterization of the
human skeletal muscle proteome by
one-dimensional gel electrophoresis and
HPLC-ESI-MS/MS. Mol Cell Proteomics
2008;7:257–267.
17. Deshmukh AS, Murgia M, Nagaraj N,
Treebak JT, Cox J, Mann M. Deep proteo-
mics of mouse skeletal muscle enables
quantitation of protein isoforms, metabolic
pathways, and transcription factors. Mol
Cell Proteomics 2015;14:841–853.
18. Murgia M, Nagaraj N, Deshmukh AS, Zeiler
M, Cancellara P, Moretti I, et al. Single
muscle ﬁber proteomics reveals unex-
pected mitochondrial specialization. EMBO
Rep 2015;16:387–395.
19. Brocca L, Cannavino J, Coletto L, Biolo G,
Sandri M, Bottinelli R, et al. The time
course of the adaptations of human muscle
proteome to bed rest and the underlying
mechanisms. J Physiol 2012;590:
5211–5230.
20. Staunton L, Zweyer M, Swandulla D,
Ohlendieck K. Mass spectrometry-based
proteomic analysis of middle-aged vs. aged
vastus lateralis reveals increased levels of
carbonic anhydrase isoform 3 in senescent
human skeletal muscle. Int J Mol Med
2012;30:723–733.
21. Doran P, Donoghue P, O’Connell K, Gannon
J, Ohlendieck K. Proteomics of skeletal mus-
cle aging. Proteomics 2009;9:989–1003.
22. Doran P, Martin G, Dowling P, Jockusch H,
Ohlendieck K. Proteome analysis of the
dystrophin-deﬁcient MDX diaphragm
reveals a drastic increase in the heat shock
protein cvHSP. Proteomics 2006;6:
4610–4621.
23. Gillet LC, Navarro P, Tate S, Rost H,
Selevsek N, Reiter L, et al. Targeted data
extraction of the MS/MS spectra gener-
ated by data-independent acquisition: a
new concept for consistent and accurate
proteome analysis. Mol Cell Proteomics
2012;11: doi:10.1074/mcp.O111.016717.
O111 016717
24. Greig CA, Young A, Skelton DA, Pippet E,
Butler FM, Mahmud SM. Exercise studies
with elderly volunteers. Age Ageing
1994;23:185–189.
25. Baumgartner RN, Koehler KM, Gallagher D,
Romero L, Heymsﬁeld SB, Ross RR, et al.
Epidemiology of sarcopenia among the
elderly in New Mexico. Am J Epidemiol
1998;147:755–763.
26. Schubert OT, Gillet LC, Collins BC, Navarro
P, Rosenberger G, Wolski WE, et al. Build-
ing high-quality assay libraries for targeted
analysis of SWATH MS data. Nat Protoc
2015;10:426–441.
27. Rosenberger G, Koh CC, Guo T, Röst HL,
Kouvonen P, Collins BC, et al. A repository
of assays to quantify 10,000 human pro-
teins by SWATH-MS. Scientiﬁc Data
2014;1:doi:10.1038/sdata.2014.31 .http://
www.nature.com/articles/
sdata201431#supplementary-information
28. Rost HL, Rosenberger G, Navarro P, Gillet
L, Miladinovic SM, Schubert OT, et al.
OpenSWATH enables automated, targeted
Cancer cachexia proteome characterization 15
Journal of Cachexia, Sarcopenia and Muscle 2017
DOI: 10.1002/jcsm.12188
analysis of data-independent acquisition
MS data. Nat Biotechnol 2014;32:
219–223.
29. Rosenberger G, Ludwig C, Rost HL,
Aebersold R, Malmstrom L. aLFQ: an
R-package for estimating absolute protein
quantities from label-free LC–MS/MS
proteomics data. Bioinformatics 2014;30:
2511–2513.
30. Teo G, Kim S, Tsou CC, Collins B, Gingras
AC, Nesvizhskii AI, et al. mapDIA:
preprocessing and statistical analysis of
quantitative proteomics data from data in-
dependent acquisition mass spectrometry.
J Proteomics 2015;129:108–120.
31. Szklarczyk D, Franceschini A, Wyder S,
Forslund K, Heller D, Huerta-Cepas J,
et al. STRING v10: protein–protein
interaction networks, integrated over
the tree of life. Nucleic Acids Res
2015;43:D447–D452, doi:10.1093/nar/
gku1003.
32. Dahlman I, Mejhert N, Linder K, Agustsson
T, Mutch DM, Kulyte A, et al. Adipose tis-
sue pathways involved in weight loss of
cancer cachexia. Br J Cancer
2010;102:1541–1548.
33. Snyman C, Niesler CU. MMP-14 in skeletal
muscle repair. J Muscle Res Cell Motil
2015;36:215–225, doi:10.1007/s10974-
015-9414-4.
34. Henningsen J, Rigbolt KT, Blagoev B, Peder-
sen BK, Kratchmarova I. Dynamics of the
skeletal muscle secretome during myoblast
differentiation. Mol Cell Proteomics
2010;9:2482–2496.
35. Mizuno K. Signaling mechanisms and
functional roles of coﬁlin phosphorylation
and dephosphorylation. Cell Signal
2013;25:457–469.
36. Remels AH, Gosker HR, Schrauwen P,
Hommelberg PP, Sliwinski P, Polkey M,
et al. TNF-alpha impairs regulation of mus-
cle oxidative phenotype: implications for
cachexia? FASEB journal: ofﬁcial
publication of the Federation of American
Societies for Experimental Biology
2010;24:5052–5062.
37. Ebhardt HA, Root A, Sander C, Aebersold R.
Applications of targeted proteomics in
systems biology and translational medi-
cine. Proteomics 2015;15:3193–3208.
38. Fukawa T, Yan-Jiang BC, Min-Wen JC,
Jun-Hao ET, Huang D, Qian CN, et al.
Excessive fatty acid oxidation induces mus-
cle atrophy in cancer cachexia. Nat Med
2016;22:666–671.
39. Jagoe RT, Goldberg AL. What do we re-
ally know about the ubiquitin–
proteasome pathway in muscle atrophy?
Curr Opin Clin Nutr Metab Care
2001;4:183–190.
40. Bodine SC, Latres E, Baumhueter S, Lai VK,
Nunez L, Clarke BA, et al. Identiﬁcation of
ubiquitin ligases required for skeletal
muscle atrophy. Science 2001;294:
1704–1708.
41. Masiero E, Agatea L, Mammucari C, Blaauw
B, Loro E, Komatsu M, et al. Autophagy is
required to maintain muscle mass. Cell
Metab 2009;10:507–515.
42. Mammucari C, Milan G, Romanello V,
Masiero E, Rudolf R, Del Piccolo P, et al.
FoxO3 controls autophagy in skeletal
muscle in vivo. Cell Metab
2007;6:458–471.
43. von Haehling S, Morley JE, Coats AJ, Anker
SD. Ethical guidelines for publishing in the
Journal of Cachexia, Sarcopenia and Mus-
cle: update 2015. J Cachexia Sarcopenia
Muscle 2015;6:315–316.
16 H. A. Ebhardt et al.
Journal of Cachexia, Sarcopenia and Muscle 2017
DOI: 10.1002/jcsm.12188
